loading page

Evaluation of the immunological response of patients with childhood cancer treated with the personalized peptide vaccine for refractory soft tissue sarcoma: An early phase II study
  • +3
  • Keiko Oda,
  • Yasuhiko Ito,
  • Akira Yamada,
  • Shigeru Yutani,
  • Kyogo Itoh,
  • Shuichi Ozono
Keiko Oda
College of Healthcare Management

Corresponding Author:[email protected]

Author Profile
Yasuhiko Ito
Nagoya City University
Author Profile
Akira Yamada
Kurume University Cancer Vaccine Center
Author Profile
Shigeru Yutani
Kurume University Cancer Vaccine Center
Author Profile
Kyogo Itoh
Kurume University Cancer Vaccine Center
Author Profile
Shuichi Ozono
Kurume University
Author Profile


We evaluated the peptide-specific immunoglobulin G (IgG) response and the safety of the personalized peptide vaccine in four children with refractory solid cancer. Although the pre-vaccination IgG responses were suppressed compared to those observed in children with upper respiratory tract infection, IgG levels against the vaccinated peptides after 12 times vaccination increased in all the three cases tested. Vaccination-related adverse effects were grade 1 injection-site local skin lesions. One patient had maintained remission for 37 months. The remaining three patients exhibited progressive disease. These results indicate the next steps in phase II studies considering their immune boosting effect and safety.